Secretin

Lynch Syndrome

Johns Hopkins Universityprotein_peptidePhase 3Active

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 95/ 100

Competitive context

18 Active assets in the Lynch Syndrome cohort.

Asset / Sponsor	Phase	Rating
Aspirin M.D. Anderson Cancer Center	Phase 3	BB
Atezolizumab National Cancer Institute (NCI)	Phase 3	B
Xaliplatin National Cancer Institute (NCI)	Phase 3	B
Acetylsalicylic Acid Lysinate Assistance Publique - Hôpitaux de Paris	Phase 3	B
Naproxen M.D. Anderson Cancer Center	Phase 2	B

View all 25 →

Same molecule, other indications

Secretin is also rated in:

pancreatic intraductal papillary-mucinous neoplasmActive

B

Indicative · Phase 3

60 / 100

malignant pancreatic neoplasmActive

CCC

Indicative · Phase 3

54 / 100

schizophreniaDormant

CCC

Indicative · Phase 2

51 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.